Research and Development of In Vitro Pharmacotoxicology: A European Perspective 1

Abstract

The experts taking part in the Workshop were: E. Rodríguez-Farré (Coordinator); G.N. Fracchia, (Secretary); M. Adolphe, École des Hautes Études, Paris, France); P.H. Bach (University of East London, UK); M. Baeder (Hoechst Ltd, Hattersheira, Germany); R. Bass (BGA, Berlin, Germany); H.G. Baumgarten (Frei Universität, Berlin, Germany); H. Bazin (DGXII, CEC, Brussels, Belgium); P. Bentley (Ciba-Geigy, Basle, Switzerland); A. Boobis (Royal Postgraduate Medical School, London, UK); J. Castell (Hospital La Fé, Valencia, Spain); J.P. Contzen (DGXII, CEC, Brussels, Belgium); A. Cordier (Sandoz Pharma Ltd, Basle, Switzerland); J. Diezi (Université de Lausanne, Switzerland); L. Dubertret (INSERM U-312, Creteil, France); P.M. Fasella (DGXII, CEC, Brussels, Belgium); J.H. Fentem (FRAME, Nottingham, UK); A. Guillouzo (INSERM U-49, Rennes, France); I. Kimber (Zeneca, Macclesfield, UK); T. Krieg (Universität zu Koln, Germany); A. Mantovani (Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy); K. Miller (BIBRA, Carshalton, UK); J.P. Morin (INSERM U-295, Rouen, France); D. Paul (Fraunhofer Institut für Toxikologie und Aerosolforschung, Hannover, Germany); P.W.J. Peters (Riijkinstituut voor Volksgezondheid en Milieuhygiene, Bilthoven, The Netherlands); J. Picard (Faculté des Sciences, Louvain la Neuve, Belgium); D. Poggiolini (Ministry of Health, Rome, Italy); C.M. Regan (University College, Dublin, Ireland); C.A. Reinhardt (SIAT, Zurich, Switzerland); B. Robaire (McGill University, Montreal, Canada); M. Roberfroid (Université Catholique de Louvain, Brussels, Belgium); V. Rogiers (Vrije Universiteit Brussels, Belgium); J. Rueff (Istituto de Higiene e Medicina Tropical, Lisbon, Portugal); H. Spielmann (ZEBET, Berlin, Germany); H. Stolte (Medizinische Hochschule, Hannover, Germany); J. van Noordwijk (European Pharmacopeia Commission, Bosch en Duin, The Netherlands); E. Walum (University of Stockholm, Sweden); D.C. Williams (Trinity College, Dublin, Ireland); and M. Yaniv (Institut Pasteur, Paris, France), and their contributions are gratefully acknowledged.

Get full access to this article

View all access options for this article.

References

D'Arcy

P.F.

, & Harron

D.W.G.

eds (1992). Proceedings of the First International Conference on Harmonisation, Brussels 1991. 590 pp. Belfast: Queen's University.

Rawlins

, Fracchia

G.N.

, & Rodríguez-Farré

(1993). Pharmacovigilance and research: a European perspective. Pharmacoepidemiology and Drug Safety 1, 261–268.

Anon. (1991). OECD Health Data. Paris: OECD.

DiMasi

J.A.

, Hansen

R.W.

, Grabowski

H.G.

, and Lasagna

(1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics 10, 107–142.

Stark

D.M.

, and Shopsis

(1983). Developing alternative assay systems for toxicity testing. Annals of the New York Academy of Sciences 406, 92–103.

Frazier

J.M.

ed. (1992). In Vitro Toxicity Testing: Applications to Safety Evaluation. New York: Marcel Dekker Inc.

Gettings

S.D.

(1991). The current status of in vitro test validaton (evaluation) in the United States. ATLA 19, 432–436.

Roberfroid

, and Goethals

(1992). In vitro pharmaco-toxicology: past, present and future. In In Vitro Alternatives to Animal Pharmaco-Toxicology (ed. Castell

J.V.

, & Gómez-Lechón

M.J.

), pp. 17–41. Madrid: Farmaindustria.

Anon. (1993). Guidelines for the Testing of Chemicals. Paris: OECD, in press.

10.

Anon. (1984). Toxicity Testing: Strategies to Determine Needs and Priorities, 382 pp. Washington, DC: National Academy Press.

11.

Anon. (1992). IRDAC Report: Opinion on Biomedical Research, 109 pp. Brussels: CEC.

12.

Anon. (1986). Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes. Official Journal of the European Communities L358, 1–28.

13.

Anon. (1988). Use of Laboratory Animals in Biomedical and Behavioural Research. Washington, DC: National Academy Press.

14.

Caplan

L.C.

(1983). Ethical issues in animal experimentation. Annals of the New York Academy of Sciences 406, 159–169.

15.

Castell

J.V.

, & Gómez-Lechón

M.J.

eds (1992). In Vitro Alternatives to Animal Pharmaco-Toxicology, 413 pp. Madrid: Farmaindustria.

16.

Aldridge

W.N.

(1981). Mechanisms of toxicity: new concepts are required in toxicology. Trends in Pharmacological Sciences 2, 228–231.

17.

Frazier

(1990). Scientific criteria for validation of in vitro toxicity tests. OECD Environment Monographs 36, 3–62.

18.

Balls

, Bridges

, and Southee

eds (1991). Animals and Alternatives in Toxicology: Present Status and Future Prospects, 390 pp. Basingstoke, UK: MacMillan Press.

19.

Veronesi

(1992). In vitro screening batteries for neurotoxicants. Neurotoxicology 13, 185–195.

20.

Ekwall

(1992). Validation of in vitro cytotoxicity tests. In In Vitro Alternatives to Animal Pharmaco-Toxicology (ed. Castell

J.V.

, & Gómez-Lechón

M.J.

), pp. 361–390. Madrid: Farmaindustria.

21.

Purchase

I.F.H.

(1990). Strategic considerations in industry's use of in vitro toxicology. Toxicology in Vitro 4, 667–674.

22.

Flint

O.P.

(1992). In vitro test validation: a house built on sand. ATLA 20, 196–198.

23.

Zbinden

(1992). The place of in vitro methods in biomedical research. In The Brain in Bits and Pieces: In Vitro Techniques in Neurobiology, Neuropharmacology and Neurotoxicology (ed. Zbinden

), pp. 11–21. Zollikon, Switzerland: MTC Verlag.

24.

Contzen

J.P.

, and Fracchia

G.N.

(1992). Pharmaceutical Research in the European Community. In In vitro Alternatives to Animal Pharmacotoxicology (ed. Castell

J.V.

, & Gómez-Lechón

M.J.

), pp. 391–396. Madrid: Farmaindustria.